PHARMACEUTICAL COMPOSITION CONTAINING (R)-N-[1-(3,5-DIFLUORO-4-METHANSULFONYLAMINO-PHENYL)-ETHYL]-3-(2-PROPYL-6-TRIFLUOROMETHYL-PYRIDIN-3-YL)-ACRYLAMIDE

PHARMACEUTICAL COMPOSITION CONTAINING (R)-N-[1-(3,5-DIFLUORO-4-METHANSULFONYLAMINO-PHENYL)-ETHYL]-3-(2-PROPYL-6-TRIFLUOROMETHYL-PYRIDIN-3-YL)-ACRYLAMIDE

One aspect of the present disclosure is a pharmaceutical composition which includes (R)-N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl- 6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first component and a cellulosic polymer as a second component, wherein the composition of one...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: CHOI, Joon Ho, SHIN, Kwang-Hyun, WOO, Byoung Young, ROH, Jong Hwa, KIM, Min-Soo, PARK, Jae Hong, PARK, Young-Ho, CHO, Won Kyung, LEE, Ki-Wha, PARK, Mi Young, PARK, Eun Sil
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:One aspect of the present disclosure is a pharmaceutical composition which includes (R)-N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl- 6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first component and a cellulosic polymer as a second component, wherein the composition of one aspect of the present disclosure has a formulation characteristic in which crystal formation is delayed for a long time.